AbbVie’s patent on immunology therapy rejected
Good news for Indian patients as the Patent Office rejected AbbVie’s Rinvoq patent, citing obviousness and lack of inventive step. This decision, crucial for affordable generic versions, prevents patent ‘evergreening’ and upholds India’s patent law. Generic manufacturers had opposed the application, leading to extensive hearings. Rinvoq treats autoimmune diseases and has significant global sales.🕒 1 min read
Good news for Indian patients as the Patent Office rejected AbbVie’s Rinvoq patent, citing obviousness and lack of inventive step. This decision, crucial for affordable generic versions, prevents patent ‘evergreening’ and upholds India’s patent law. Generic manufacturers had opposed the application, leading to extensive hearings. Rinvoq treats autoimmune diseases and has significant global sales.
Continue Reading
- Gautam Adani Unveils Big Bet On Nuclear Power, AI, Infrastructure
-
“A Guy Who Never Dies”: Trump Urges MAGA Base To End ‘Epstein Files’ Obsession
- Web based casinos are generally known for providing some incentives to draw the new players and offer pro rewards
-
Trump Holds Off On Planned Iran Strike After Gulf Allies’ Request
-
Government allows 15 banks to import gold & silver until March 2029; permission amid tons of metals stuck in customs
- Zee shareholders block Rs 2k crore infusion in setback to founder
- OrientXpress 21 Prive 50 free spins no deposit required Gambling enterprise Review 2025: Video game, Bonuses & Has
- Food Delivery Agent Attacks Odisha Woman During Argument Over Delay
- Asia Cup: On opening day, Rashid Khan slams scheduling as captains voice frustration
-
IND vs ENG: ‘I missed my triple hundred’ – Gill gets emotional after parents’ message